The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge ...

The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market ...

AstraZeneca's shares have fallen more than 8% on speculation about an anti-corruption probe in China, its second-largest ...

Scientists at the Johns Hopkins Kimmel Cancer Center have identified 16 genes that breast cancer cells use to survive in the bloodstream after they've escaped the low-oxygen regions of a tumor.

In related news, the American Diabetes Association released new consensus considerations and good-practice points for use of ...

Fewer healthcare workers are getting the most recent COVID-19 booster. Findings from a new CDC survey show that 15.3 percent ...

AstraZeneca shares declined Tuesday after reports that senior executives in China were potentially implicated in an insurance ...

BofA notes that AstraZeneca (AZN) shares are down greater than 10% in the last few days on the back of China concerns around the ongoing ...

(Alliance News) - AstraZeneca PLC on Tuesday took the rare step of addressing a sharp fall in the company's share price. Shares in the Cambridge-based pharmaceuticals company slumped 8.2% to 10,138.10 ...

Analyst Etzer Darout of BMO Capital maintained a Buy rating on AstraZeneca (AZN – Research Report), retaining the price target of $89.00.

AstraZeneca's (NASDAQ:AZN) selloff on Tuesday in response to reports that the company is facing a fraud investigation in ...

AstraZeneca’s stock price dropped by 8.4% during Tuesday’s trading in London after a report fueled fears of a potentially ...